Introduction
Spontaneous retroperitoneal haemorrhage is an unusual but well recognized occurrence in patients receiving anticoagulant therapy (Curry and Bacon, 1974) as well as in haemophiliacs (van Trotsenburg, 1975) . Three recent series have suggested that retroperitoneal bleeding in patients receiving intravenous heparin is commoner than previously recognized, the incidence being 4.3-6.6% (UrokinasePulmonary Embolism Trial, 1973; Curry and Bacon, 1974; Mant et al., 1977) . Reports of fatal cases are, however, rare (Flanc, Kakkar and Clarke, 1968;  Curry and Bacon, 1974) . Recent 
Discussion
Eight patients receiving anticoagulant therapy have been described who developed extensive retroperitoneal haemorrhage which was verified at postmortem and believed to contribute to death. Only a few isolated cases of this fatal complication have been hitherto reported (Flanc et al., 1968; Curry and Bacon, 1974 Basu et al., 1972; Mant et al., 1977) . In only 2 patients was regular monitoring of clotting times performed. Whether or not monitoring of heparin infusion reduces bleeding complications is unknown. In the 2 patients in whom whole blood clotting time was monitored it was never excessively prolonged: the range of 10-12 min in these patients would be regarded by several authors as indicating inadequate doses of heparin. However, as there is some evidence for an association between prolonged clotting times and bleeding (O'Sullivan et al., 1968; Urokinase-Pulmonary Embolism Trial, 1973 ) detection of excessive anticoagulant effect (as was belatedly discovered in case 7) and its correction might prevent at least some haemorrhages. Haemorrhage did not become manifest until after several days of heparin. The authors' clinical impression that the risk of all types of bleeding complication increases after the first 2 days of heparin treatment is in agreement with that of Mant et al. (1977) . Possible reasons for this might be reduction in the anti-heparin activity of blood which is present in the acute stages of thrombosis (Dewhurst and Poller, 1965) , and the thrombocytopenia which may develop after several days' heparin infusion (Bell et al., 1976) . Three patients also received warfarin: monitoring was not performed in one case, and revealed excessive anticoagulant effect (thrombotest less than 5¼/) in the other 2 on at least one day. In 2 patients drug interactions may have increased the effects of anticoagulants-concurrent administration of dextran and heparin in case 2, and co-trimoxazole and warfarin in case 8.
Although retroperitoneal haemorrhage is an unusual cause of death in patients on anticoagulants, it may be more frequent than previously noted. It was not possible for the authors to ascertain the total incidence of fatal retroperitoneal bleeding in patients receiving heparin infusions in Glasgow during the study period. Sudden circulatory collapse might be misinterpreted as a recurrence of the primary problem for which anticoagulants were given, for example pulmonary embolism, and unless postmortem examination is carried out the true cause of death may be missed. The true incidence of fatal retroperitoneal haemorrhage might thus be underestimated. Recent reports suggest that the incidence of all forms of retroperitoneal haemorrhage in patients receiving heparin infusions is about 5V/ (Urokinase-Pulmonary Embolism Trial, 1973; Curry and Bacon, 1974; Mant et al., 1977) . Increased awareness of this potentially lethal complication may lead to earlier diagnosis, earlier treatment, and reduced mortality.
